BRIEF-Pharming Group FY net loss narrows to 5.8 mln euros

* FY revenues from operations increased to 21.2 million euros ($23.4 million) (2013: 6.8 million euros)

Earnings, Stocks, Markets 1:19am EST

UPDATE 1-AbbVie to buy cancer drug maker Pharmacyclics in $21 bln deal

March 4 - Drugmaker AbbVie Inc said it will buy Pharmacyclics Inc, the maker of blockbuster cancer drug Imbruvica, for about $21 billion to boost its oncology drugs pipeline.

Stocks, M&A, Markets, 04 Mar 2015

UPDATE 3-Second Los Angeles hospital identifies 'superbug' infections

LOS ANGELES, March 4 - A second top Los Angeles hospital has reported an outbreak of drug-resistant "superbug" infections, and dozens more potential exposures, from procedures performed with a fiber-optic instrument called a duodenoscope.

AbbVie to buy Pharmacyclics in $21 billion deal

March 4 - AbbVie Inc said it will buy cancer drug company Pharmacyclics Inc in a $21 billion deal.

Stocks, M&A, Markets 04 Mar 2015

Crowdfunding psychedelics: LSD brain-imaging study seeks funds

LONDON, March 5 - British scientists are turning to crowdfunding to complete the first scientific study ever to image the brain of someone "tripping" on the psychedelic drug LSD.

04 Mar 2015


  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Renaissance Capital
Provider: Renaissance Capital
Provider: Renaissance Capital
Provider: Renaissance Capital
Provider: Renaissance Capital

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.